US Stock Market Move | Lilly (LLY.US) rises against the trend by more than 3%, hitting a new all-time high.

On Friday, the stock price of Eli Lilly (LLY.US) rose against the trend, with an intraday increase of over 3%, continuing to hit historical highs, with a total market value of $1.09 trillion. On the news front, Eli Lilly's popular weight loss drug Zepbound recently regained insurance coverage from the American pharmaceutical giant CVS Caremark, and the newly approved oral weight loss drug Foundayo was also included in the prescription collection. The GLP-1 product matrix continues to expand. In the current scenario of capital rotation from technology stocks to value sectors such as healthcare and finance in the US stock market, Eli Lilly has become a core target for safe haven funds due to its strong fundamentals and leading position in the weight loss drug track. Citigroup reiterated a "buy" rating for Eli Lilly with a target price of $1500. An upcoming diabetes conference is expected to announce more data on retatrutide, which is expected to further highlight the drug's differentiation advantages from existing products and support its broader application.